Merck announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] 1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, who have received one or two prior systemic treatment regimens. These approvals mark an important moment for the ovarian cancer community, reflecting years of focused investment in KEYTRUDA. KEYTRUDA and KEYTRUDA QLEX are each indicated, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA- authorized test.
KEYTRUDA and KeyTRUDA QLEX is each indicated, in combination with fluoropyrimidine- and Platinum-containing chemotherapy, for the First-line treatment of adults with local advanced unresectable or metastatics HER2-positive gastric and gastroesophageal junction ("GEJ") adenocarcinoma its tumors express PD-L1 ("CPS 1") as determined by an FDA- authorization test. KEYTRUDA & KEYTRUDA QLE X are each indicated, in combination With trastuzumab, Fluopyrimidine- and platinum -based chemotherapy for patients with tumors that express PD-L1 (CPS 1), or as a single agent after one or more prior lines of systemic therapy for patients of squamous cell histology that express PD-L1.
